Enhancing Drug Safety in Pregnancy with INRIM’s Optimised Resazurin Assay

In the pursuit of safer pharmaceutical interventions during pregnancy, it is critical to have reliable and precise preclinical data. The LIFESAVER project, dedicated to advancing risk assessment for drugs and chemicals affecting pregnant women, heavily relies on innovative methodologies to ensure drug safety and efficacy. One pivotal contribution to this mission comes from INRIM, whose recent publication focuses on optimising the resazurin-based viability assays, a cornerstone technique in cell biology and pharmacotoxicology.

The Resazurin assay, also known commercially as Alamar Blue, is fundamental in evaluating the viability of cells—a crucial step in the assessment of drug safety. This assay operates on a simple yet powerful premise: resazurin, a non-fluorescent dye, is converted into a fluorescent resorufin in response to chemical reduction by cellular enzymes, an indication of metabolic activity. The intensity of the fluorescence directly correlates with the number of living cells, providing an invaluable metric for determining the cytotoxic effects of potential pharmaceuticals.

The research led by INRIM, detailed in their publication, aims to address and minimise critical inconsistencies found in existing laboratory protocols that utilise the resazurin assay. These inconsistencies often lead to unreliable data, significantly hampering progress in drug safety evaluations. INRIM’s study rigorously defines standardised procedures to enhance the reliability and reproducibility of this assay. Key optimisations include specific guidelines on incubation times, wavelength settings for fluorescence measurement, and stringent criteria for experimental precision—essential for reducing variability in data and improving the interpretability of toxicity assessments.

Laboratory protocols enhance the reliability of drug safety assessments

Jessica Petiti of INRIM explains, “Our work at INRIM is focused on refining laboratory protocols to enhance the reliability of drug safety assessments. These improvements are crucial for ensuring the health and safety of pregnant women and their babies.” This underscores the importance of their research in advancing drug safety.

For the LIFESAVER project, these optimised protocols mean more than just technical improvements; they represent a significant leap towards enhancing maternal and fetal safety during drug development. By adopting these standardised procedures, researchers can generate more consistent and reliable data, facilitating better decision-making in the early stages of drug development and potentially reducing the reliance on animal testing. This advancement aligns perfectly with LIFESAVER’s goal of employing cutting-edge science to protect mother and child without compromising ethical standards.

To aid understanding, let’s demystify some technical aspects: the transition from resazurin to resorufin in this assay isn’t just a chemical reaction—it’s a beacon indicating cell health. Healthy, active cells reduce more resazurin, thus emitting brighter fluorescence. This change is measured quantitatively by scientists to gauge the impact of drugs on cellular functions, crucial for determining potential risks in pregnant women.

LIFESAVER is paving the way for more sophisticated digital and automated platforms for drug testing

The standardisation of the resazurin assay by INRIM has broader implications beyond the LIFESAVER project. It sets a benchmark for laboratories around the world, promoting more accurate and reliable biological assessments in various scientific fields. This standardisation is particularly beneficial for developing countries, where laboratory resources may be limited, by providing a low-cost and effective method to test drug safety.

Looking forward, the adoption of standardised protocols like those developed by INRIM could pave the way for more sophisticated digital and automated platforms for drug testing. These technologies promise to further enhance the accuracy and efficiency of preclinical trials, reducing both the time and cost associated with bringing safer, more effective drugs to market.

The work done by INRIM is a cornerstone in building safer pharmaceutical practices. By ensuring the accuracy and consistency of cytotoxicity data through standardised resazurin assays, we are one step closer to achieving safer pregnancy outcomes. This development not only supports the LIFESAVER project’s objectives but also sets a new standard in preclinical testing that could be adopted globally, enhancing drug safety assessments across the board.

The full details of INRIM’s standardised procedure, which could revolutionise how drug safety is evaluated in pregnancy, are accessible in their open-access paper. For anyone involved in pharmaceutical development, especially in contexts impacting maternal health, this publication is an essential read.

For more insights into how LIFESAVER leverages such innovative research to enhance prenatal safety, visit the LIFESAVER project’s website. Here, you can also find updates on other research outputs and initiatives under the LIFESAVER umbrella, driving forward the frontier of maternal and fetal health safety.